CADENCE

CADENCE makes Parkinson's disease trials smarter and more cost-effective. This AI-driven pipeline pinpoints the common, ancestry-specific risk alleles that define genetic subtypes — enabling precision enrollment so expensive trials recruit the right patients from the start. Validated in Parkison's disease database (PPMI), these alleles are enriched in real patients and biomarker status tracks genotype. Built with Claude, from public data to trial-ready insight.